Valneva (VALN) has released an update.
Valneva SE and LimmaTech Biologics AG have received FDA Fast Track designation for their tetravalent Shigella vaccine candidate, S4V, showcasing significant potential to address a major global health threat. This designation aims to expedite the vaccine’s development and review process to combat the deadly shigellosis disease, which affects millions annually. Valneva plans to advance further development and commercialization of the vaccine worldwide, pending approval.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
